

**Preferred Drug List Committee  
Meeting Agenda, Open Session  
June 12, 2019 11:30am to 1:00pm**

**Meeting Location**

DXC Technology (formerly HP Enterprise Services) Capital Room  
6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

**Committee Members**

Jessica Bates, PharmD., BCPS	Megan Hedden, PharmD.
Emily Blew, PharmD.	William Pankey, M.D.
Taylor Gill, PharmD., BCPS	James Rider, M.D.
Katherine Grimsley, M.D.	Donna Sweet, M.D.
Robert Haneke, Pharm.D.	Wayne Wallace, M.D.

**KDHE-DHCF/Contractor Staff**

Annette Grant, RPh	Markie O'Donnell, Transcriptionist
Victor Nguyen, Pharm.D.	

**DXC Technology Staff**

Karen Kluczykowski, RPh.	Kathy Kaesewurm, RN, BSN
--------------------------	--------------------------

- I. Call to Order
  - a. Announcements and Introductions
- II. Review & Approval of Meeting Minutes from 03/13/2019.
- III. Old Business
  - a. Consent Agenda Items
    - i. PDL New Drug Placements
      - 1. Actemra<sup>®</sup> ACTpen<sup>™</sup>
      - 2. Adhansia XR<sup>™</sup>
      - 3. Jatenzo<sup>®</sup>
      - 4. Lexette<sup>™</sup> Foam
      - 5. Lotemax<sup>®</sup> SM
      - 6. Proair<sup>®</sup> Digihaler<sup>™</sup>
      - 7. Promacta<sup>®</sup> Powder Packets
      - 8. Qmiiz ODT
      - 9. Tosymra<sup>™</sup>
      - 10. Tresiba<sup>®</sup> Vial
    - ii. Committee discussion/Recommendations

#### IV. New Business

- a. Request to Separate the Topical Acne Agents into Subclasses.
  - i. Public Comment
  - ii. Committee Discussion/Recommendations
- b. Addition of Remicade biosimilars to the PDL classes which already contain Remicade.
  - i. Public Comment
  - ii. Committee Discussion/Recommendations
- c. Immunomodulation Agents – Asthma - New Class (Cinqair®, Dupixent®, Fasenra™, Nucala®, Xolair®).
  - i. Public Comment
  - ii. Committee Discussion/Recommendations
- d. Overview of the PDL Program.
  - i. Presentation by KDHE
  - ii. Committee Discussion
- e. New PDL Committee Chairperson.
  - i. Nominations by PDL Committee members
  - ii. Voting
- f. New PDL Committee Interim Chairperson.
  - i. Nominations by PDL Committee members
  - ii. Voting

#### V. Open Public Comment

#### VI. Adjourn

**\*\*THIS AGENDA IS SUBJECT TO CHANGE\*\***